AVACTA GROUP PLC
Clinical-stage biotech developing targeted oncology drugs with a proprietary platform.
AVCT | IL
Overview
Corporate Details
- ISIN(s):
- GB00BYYW9G87
- LEI:
- 2138009U3EG31OPMGH36
- Country:
- United Kingdom
- Address:
- UNIT 20 ASH WAY, THORP ARCH ESTATE, LS23 7FA WETHERBY
- Website:
- https://avacta.com/
- Sector:
- Manufacturing
Description
Avacta Group PLC is a clinical-stage biotechnology company developing targeted oncology drugs. The company's core technology is the proprietary pre|CISION® platform, a drug delivery system designed to improve the safety and efficacy of potent cancer therapies. The platform works by linking a peptide to a cancer drug, rendering it inactive in the bloodstream. The drug is precisely activated only within the tumor microenvironment by the Fibroblast Activation Protein (FAP) enzyme, which is abundant in many solid tumors. This approach aims to concentrate the active therapy at the tumor site, thereby reducing systemic toxicity and improving the therapeutic window for patients. The company is advancing a pipeline of peptide drug conjugates (PDCs) based on this platform.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-08 08:35 |
Preliminary Data in Faridoxorubicin Phase 1b Trial
|
English | 15.8 KB | ||
| 2025-11-03 09:45 |
Completion of Placing and TVR
|
English | 15.7 KB | ||
| 2025-10-27 18:39 |
Block Listing Six Monthly Return
|
English | 27.8 KB | ||
| 2025-10-20 08:01 |
Equity fundraise of £16 million
|
English | 45.3 KB | ||
| 2025-10-20 08:00 |
Avacta Presents Phase 1a Data for Faridoxorubicin
|
English | 30.5 KB | ||
| 2025-10-13 08:00 |
Avacta to present data at EORTC-NCI-AACR
|
English | 22.7 KB | ||
| 2025-09-15 08:00 |
Notice of Interim Results
|
English | 17.8 KB | ||
| 2025-09-09 08:00 |
Shortlisted for AIM Awards Technology of the Year
|
English | 15.2 KB | ||
| 2025-07-30 08:00 |
Avacta to Present at ESMO Congress
|
English | 17.3 KB | ||
| 2025-07-28 08:48 |
Agreement to Sell Coris Bioconcept SRL
|
English | 17.8 KB | ||
| 2025-07-21 08:00 |
Payment of Convertible Bond Installment
|
English | 16.0 KB | ||
| 2025-07-17 08:00 |
Equity fundraise of £3.25 million
|
English | 42.4 KB | ||
| 2025-07-02 18:00 |
Result of AGM
|
English | 29.4 KB | ||
| 2025-07-02 08:00 |
Q2 2025 Business Update
|
English | 25.6 KB | ||
| 2025-06-06 08:00 |
Preliminary Full Year 2024 Results
|
English | 512.2 KB |
Automate Your Workflow. Get a real-time feed of all AVACTA GROUP PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for AVACTA GROUP PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for AVACTA GROUP PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
